0001209191-20-013025.txt : 20200226
0001209191-20-013025.hdr.sgml : 20200226
20200226163254
ACCESSION NUMBER: 0001209191-20-013025
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200224
FILED AS OF DATE: 20200226
DATE AS OF CHANGE: 20200226
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kewalramani Reshma
CENTRAL INDEX KEY: 0001735944
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 20656252
MAIL ADDRESS:
STREET 1: C/O VERTEX PHARMACEUTICALS, INC.
STREET 2: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-02-24
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001735944
Kewalramani Reshma
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
1
1
0
0
EVP and CMO
Common Stock
2020-02-24
4
F
0
2898
239.23
D
30260
D
Common Stock
2020-02-25
4
S
0
893
229.72
D
29367
D
Common Stock
2020-02-25
4
S
0
450
230.88
D
28917
D
Common Stock
2020-02-25
4
S
0
440
232.35
D
28477
D
Common Stock
2020-02-25
4
S
0
660
234.41
D
27817
D
Common Stock
2020-02-25
4
S
0
340
235.36
D
27477
D
Common Stock
2020-02-25
4
S
0
320
236.71
D
27157
D
Common Stock
2020-02-25
4
S
0
420
238.28
D
26737
D
Common Stock
2020-02-25
4
S
0
111
239.13
D
26626
D
Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1.
Open market sales reported on this line occurred at a weighted average price of $229.72 (range $229.23 to $230.17).
Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $230.88 (range $230.48 to $231.38).
Open market sales reported on this line occurred at a weighted average price of $232.35 (range $232.14 to $233.08).
Open market sales reported on this line occurred at a weighted average price of $234.41 (range $233.90 to $234.80).
Open market sales reported on this line occurred at a weighted average price of $235.36 (range $235.13 to $235.56).
Open market sales reported on this line occurred at a weighted average price of $236.71 (range $236.31 to $237.24).
Open market sales reported on this line occurred at a weighted average price of $238.28 (range $238.01 to $238.54).
Open market sales reported on this line occurred at a weighted average price of $239.13 (range $239.13 to $239.14).
/s/ Omar White, Attorney-in-Fact
2020-02-26